Web Release Date: February 18,
In Vivo Stability and Photodynamic Efficacy of Fluorinated Bacteriopurpurinimides Derived from Bacteriochlorophyll-a





and 

Photodynamic Therapy Center, Department of Dermatology, and Department of Nuclear Medicine/Radiology, Roswell Park Cancer Institute, Buffalo, New York 14263, and Institute for Lasers, Photonics and Biophotonics, SUNY at Buffalo, Buffalo, New York 14260
Received September 16, 2005

Abstract:
The stable bacteriopurpurinimide (788 nm,
: 38 600 in CH2Cl2), obtained by reducing the corresponding
unstable Schiff base (803 nm,
: 50 900 in CH2Cl2) that was isolated by reacting bacteriopurpurin methyl
ester with 3,5-bis-(trifluoromethyl)benzylamine, produced promising photosensitizing efficacy. 1H NMR,
mass spectrometry, and HPLC analyses confirmed the structures of new bacteriopurpurinimides and the
metabolic product. The preliminary in vivo photosensitizing efficacy of this stable bacteriopurpurinimide
was determined in C3H mice bearing radiation induced fibrosarcoma tumors as a function of variable drug
doses. A drug dose of 1.0
mol/kg and light exposure of 135 J/cm2 (75 mW/cm2; 24 h postinjection) at 796
nm for 30 min produced a 60% long-term tumor cure (3/5 mice were tumor-free on day 90). Colocalization
study of the stable bacteriopurpurinimide with MitoTracker Green confirmed some mitochondrial localization.
The fluorescein-exclusion assay and histological staining of CD31 confirmed vascular stasis at various time
points post-PDT (post photodynamic therapy). The treatment parameters (time for maximum drug uptake
and wavelength for light irradiation) were determined by in vivo reflectance spectroscopy.
Download the full text: PDF | HTML